Pinato David J, Lombardi Pasquale, D'Alessio Antonio, Torkpour Aria, Fulgenzi Claudia Angela Maria, Brunetti Leonardo
Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom.
Department of Translational Medicine (DIMET), University of Piemonte Orientale "A. Avogadro", Novara, Italy.
Clin Cancer Res. 2025 Mar 17;31(6):955-957. doi: 10.1158/1078-0432.CCR-24-3805.
Although deemed potentially curative, surgical resection of hepatocellular carcinoma is associated with >70% risk of postoperative relapse. Recurrence is uniquely multifactorial in hepatocellular carcinoma, potentially stemming from metachronous reoccurrence of the original tumor or de novo cancerization. ctDNA may improve personalized risk stratification after resection, a setting where adjuvant immunotherapy has failed to provide survival benefit. See related article by Hu et al., p. 1047.
尽管手术切除肝细胞癌被认为具有潜在治愈性，但术后复发风险超过70%。肝细胞癌的复发具有独特的多因素性，可能源于原发肿瘤的异时性复发或新发癌变。循环肿瘤DNA（ctDNA）可能会改善切除术后的个性化风险分层，在这种情况下辅助免疫治疗未能提供生存获益。见胡等人的相关文章，第1047页。
